Tickernomics

10y

Historical Returns*:

SPY

27.80%

-36.22%

ANEB

SPY

32.66%

-75.08%

ANEB

SPY

108.59%

ANEB

0.00%

SPY

302.52%

ANEB

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

42.01

40.61

0.05

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-5.30

0.00

22.13

0.00

-7.29

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

0.00

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

4.32

-55.81

-71.16

0.00

Other Earnings and Cash Flow Stats:

Anebulo Pharmaceuticals Inc. ( ANEB ) Net Income TTM ($MM) is -7.92

Anebulo Pharmaceuticals Inc. ( ANEB ) Operating Income TTM ($MM) is -8.18

Anebulo Pharmaceuticals Inc. ( ANEB ) Owners' Earnings Annual ($MM) is 0.00

Anebulo Pharmaceuticals Inc. ( ANEB ) Current Price to Owners' Earnings ratio is 0.00

Anebulo Pharmaceuticals Inc. ( ANEB ) EBITDA TTM ($MM) is -6.19

Anebulo Pharmaceuticals Inc. ( ANEB ) EBITDA Margin is 0.00%

Capital Allocation:

Anebulo Pharmaceuticals Inc. ( ANEB ) has paid 0.00 dividends per share and bought back -0.3 million shares in the past 12 months

Anebulo Pharmaceuticals Inc. ( ANEB ) has increased its debt by 0.0 million USD in the last 12 months

Capital Structure:

Anebulo Pharmaceuticals Inc. ( ANEB ) Interest-bearing Debt ($MM) as of last quarter is 0

Anebulo Pharmaceuticals Inc. ( ANEB ) Annual Working Capital Investments ($MM) are -1

Anebulo Pharmaceuticals Inc. ( ANEB ) Book Value ($MM) as of last quarter is 1

Anebulo Pharmaceuticals Inc. ( ANEB ) Debt/Capital as of last quarter is 0%

Other Balance Sheet Stats:

Anebulo Pharmaceuticals Inc. ( ANEB ) has 1 million in cash on hand as of last quarter

Anebulo Pharmaceuticals Inc. ( ANEB ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter

Anebulo Pharmaceuticals Inc. ( ANEB ) has 25 common shares outstanding as of last quarter

Anebulo Pharmaceuticals Inc. ( ANEB ) has 0 million USD of preferred stock value

Academic Scores:

Anebulo Pharmaceuticals Inc. ( ANEB ) Altman Z-Score is -3.86 as of last quarter

Anebulo Pharmaceuticals Inc. ( ANEB ) Piotroski Score is 1.00 as of last quarter

Corporate Governance:

Anebulo Pharmaceuticals Inc. ( ANEB ) largest shareholder is owning shares at 0.00 ($MM) value

Aron R English(an insider) Bought 400 shares of Anebulo Pharmaceuticals Inc. ( ANEB ) for the amount of $2636.00 on 2021-12-17

64.22% of Anebulo Pharmaceuticals Inc. ( ANEB ) is held by insiders, and 28.18% is held by institutions

Anebulo Pharmaceuticals Inc. ( ANEB ) went public on 2021-05-07

About Anebulo Pharmaceuticals Inc. ( ANEB ) :

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.